178,545 research outputs found
O kung Fu e o desenvolvimento infantil : desenvolvimento motor
No full textEste trabalho busca elementos para verificar a ligação do Kung Fu, uma arte
marcial chinesa, com o desenvolvimento motor infantil, baseando-se no conceito do
desenvolvimento motor de GALLAHUE, D. L.; OZMUN, J. C e MEINEL, K., e assim poder
associar estes conceitos a pratica desta, que atualmente é uma das artes marciais mais praticadas
no mundo. Mas antes de apresentar o desenvolvimento motor, passa-se por uma revisão da
história do Kung Fu, e uma revisão sobre o desenvolvimento, para que se possa desenvolver
com clareza a idéia da ligação das duas coisas. Durante a pesquisa foi realizado como forma de
busca de dados, um sistema de diário de observação de alunos praticantes de Kung Fu em
diversos níveis de aprendizagem e treinamento, respeitando a faixa etária proposta pelo trabalho,
para poder apresentar conclusões consistentes. Sem aprofundar-se no tipo de treinamento
realizado e nos estilos existentes da modalidade esportiva, mas se atentando exclusivamente as
crianças no treinamento, com os dados coletados, foi possível observar uma grande relação entre
o Kung Fu e a melhora do desenvolvimento de capacidades como coordenação motora geral,
equilíbrio, lateralidade, noção de direita e esquerda, posição e sentido.This paper searches for elements to verify the connection of Kung Fu, a
Chinese martial art, with the motor development of children, based on the concept of motor
development of GALLAHUE, D. L.; OZMUN, J. C e MEINEL, K., and this way be able to
associate these concepts to it, which is currently one of the most practiced martial arts in the
world. But before presenting the motor development, it will go through a review of the history
of Kung Fu, and a review about the development, so that it can develop a clear idea of the
connection of both things. During the research it was conducted as a way of data searching, a
system of observation journal of students practicing Kung Fu at different levels of learning and
training, respecting the age proposed for the work, to present consistent conclusions. Without
going too deep into the kind of training conducted and in the different existing styles of the
sport, but exclusively paying attention to the children in training, with the collected data, it was
possible to observe a strong relation between Kung Fu and the improvement of capacities as
general motor coordination, balance, laterality, sense of right and left, position and direction
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
No full textOral capecitabine (Xeloda<sup>®</sup>) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for Health and Clinical Excellence (NICE) in the adjuvant setting. Adjuvant capecitabine is at least as effective as 5-fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival and a trend towards improved disease-free and overall survival. We assessed the cost-effectiveness of adjuvant capecitabine from payer (UK National Health Service (NHS)) and societal perspectives. We used clinical trial data and published sources to estimate incremental direct and societal costs and gains in quality-adjusted life months (QALMs). Acquisition costs were higher for capecitabine than 5-FU/LV, but higher 5-FU/LV administration costs resulted in 57% lower chemotherapy costs for capecitabine. Capecitabine vs 5-FU/LV-associated adverse events required fewer medications and hospitalisations (cost savings £3653). Societal costs, including patient travel/time costs, were reduced by >75% with capecitabine vs 5-FU/LV (cost savings £1318), with lifetime gain in QALMs of 9 months. Medical resource utilisation is significantly decreased with capecitabine vs 5-FU/LV, with cost savings to the NHS and society. Capecitabine is also projected to increase life expectancy vs 5-FU/LV. Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes' C colon cancer. This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the UK
Mutation frequencies following the 5-FU-, 4NQO-, and CPT-treatment.
No full textA), C), and E) The frequencies of overall Lys+ mutations following treatments with 5-FU (10 μM), CPT (100 μM), or 4NQO (0.2 μg/mL), respectively, for 24 hrs. B), D), and F) The frequencies of the uracil-dependent A>C and T>G mutations following treatments with 5-FU, CPT and 4NQO, respectively. Error bars indicate 95% confidence intervals. The number of cultures used to determine the frequencies of mutations and the numerical values of the median mutation frequencies and the confidence intervals represented as graphs in this figure are listed in S4 Table.</p
mDia formins are required for cell recovery in 5-FU-induced myeloid suppression.
No full text(A) The numbers of HSPCs and committed progenitors from purified lineage-negative cells were analyzed and quantified by flow cytometer analysis by day 7 after 5-FU treatment. (B) Survival percentage of lineage-negative cells from A assayed by Annexin V staining. (C) Complete blood cell counts of wild-type or mDia1 KO mice were determined by day 7 after the first injection of 5-FU. (D) Kaplan-Meier survival analysis of indicated mice challenged with serial 5-FU injection. Error bars represent the SEM of the mean. * ppppp values. (TIFF)</p
Effect of <i>BCL2A1</i> overexpression on 5-FU-resistance in MDA-MB-231 and T-47D.
No full textBCL2A1 protein expression of (A) MDA-MB-231 and (C) T-47D after transfection with a pCMV-Myc-DDK Entry vector (Vector) or a pCMV-Myc-DDK BCL2A1 vector (BCL2A1). Cytotoxicity of 5-FU toward (B) MDA-MB-231 transfected with a BCL2A1 vector and (D) T-47D transfected with a BCL2A1 vector. The insets show the IC50 of 5-FU against cell lines transfected with vectors. Data represent the mean with SEM of at least three independent samples (***pvs. MDA-MB-231 transfected with a control vector; *pvs. T-47D transfected with a control vector).</p
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats
No full textThe fatty-acid ethanolamide, oleoylethanolamide (OEA), is a naturally occurring lipid that regulates feeding and body weight [Rodriguez de Fonseca, F., Navarro, M., Gomez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodriguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., Kathuria, S., Gall, C., Piomelli, D., 2001. An anorexic lipid mediator regulated by feeding. Nature 414, 209-212], and serves as an endogenous agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) [Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth., A., Luecke, H., Di Giacomo, B., Tarzia, G., Piomelli, D., 2003. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93], a ligand-activated transcription factor that regulates several aspects of lipid metabolism [. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688]). OEA reduces food intake in wild-type mice, but not in mice deficient in PPAR-alpha (PPAR-alpha(-/-)), an effect that is also observed with the PPAR-alpha agonists Wy-14643 and GW7647 [Brown, P.J., Chapman, J.M., Oplinger, J.A., Stuart, L.W., Willson, T.M. and Wu, Z., 2000. Chemical compounds as selective activators of PPAR-alpha. PCT Int. Appl., 32; . The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550]. By contrast, specific agonists of PPAR-delta/beta (GW501516) or PPAR-gamma (ciglitazone) have no such effect. In obese Zucker rats, which lack functional leptin receptors, OEA reduces food intake and lowers body-weight gain along with plasma lipid levels. Similar effects are seen in diet-induced obese rats and mice. In the present study, we report that subchronic OEA treatment (5mgkg(-1), intraperitoneally, i.p., once daily for two weeks) in Zucker rats initiates transcription of PPAR-alpha and other PPAR-alpha target genes, including fatty-acid translocase (FAT/CD36), liver fatty-acid binding protein (L-FABP), and uncoupling protein-2 (UCP-2). Moreover, OEA decreases neutral lipid content in hepatocytes, as assessed by Oil red O staining, as well as serum cholesterol and triglyceride levels. The results suggest that OEA regulates lipid metabolism and that this effect may contribute to its anti-obesity propertie
EpCAM Aptamer Activated 5-FU-Loaded PLGA Nanoparticles in CRC Treatment; In vitro and In vivo study
No full textIn this study, EpCAM aptamer-activated nanoparticles (Ap-NPs) were synthesized to enhance treatment efficiency in colorectal cancer (CRC). PLGA [poly (D, L-lactide-co-glycolide)] copolymer was fabricated by conjugation of COOH-PEG-NH2 to PLGA-COOH through an EDC/NHS-mediated chemistry. Afterward, 5‐fluorouracil-loaded (FU) nanoparticles were prepared using the water/oil/water double emulsion solvent evaporation method. The in vitro cytotoxicity of formulations was evaluated using the MTT assay in HCT-116, CT-26, and HEK-293 cell lines. For in vivo study, tumor-bearing BALB/c mice were established by subcutaneous injection of CT-26 cell line. The results indicated that fabricated AP-FU-NPs had 101 nm size with a spherical surface, relatively homogeneously and, satisfactory encapsulation efficiency (83.93%). In vitro experiments revealed that Ap-FU-NPs had a superior in vitro cytotoxicity than both FU-NPs and free 5-FU in CT-26 and HCT-116 cells but, were significantly low toxic against HEK-293 cells relative to free 5-FU. Furthermore, in vivo results showed no significant hemolytic effect, hepatic and renal injury, or weight loss. After treatment of various animal groups with formulations, notable tumor growth delay was observed followed the order: Ap-FU-NPs The overall strategy of this study is summarized in Graphical Abstract. The present study was carried out in the three steps summarized: 1) synthesis and characterization. At first, PEG was conjugated to PLGA polymers by EDC/NHS chemistry method, then the resulting polymers were used to prepare PLGA-PEG NPs via the W/O/W technique. Finally, EpCAM Aptamers were attached to fabricated NPs. 2) In the second step cytotoxicity of formulated NPs was evaluated in vitro experiments in HEK-293, CT-26, and HCT-116 cell lines. 3) In the third step in vitro results further was investigated in CT-26 tumor-bearing BALB/c mice. “Created with BioRender.com.”</p
The (2 + 1)-d U (1) quantum link model masquerading as deconfined criticality
No full textThe (2 + 1)-d U(1) quantum link model is a gauge theory, amenable to quantum simulation, with a spontaneously broken SO(2) symmetry emerging at a quantum phase transition. Its low-energy physics is described by a (2 + 1)-d RP(1) effective field theory, perturbed by an SO(2) breaking operator, which prevents the interpretation of the emergent pseudo-Goldstone boson as a dual photon. At the quantum phase transition, the model mimics some features of deconfined quantum criticality, but remains linearly confining. Deconfinement only sets in at high temperature
MeSH term explosion and author rank improve expert recommendations
No full textInformation overload is an often-cited phenomenon that reduces the productivity, efficiency and efficacy of scientists. One challenge for scientists is to find appropriate collaborators in their research. The literature describes various solutions to the problem of expertise location, but most current approaches do not appear to be very suitable for expert recommendations in biomedical research. In this study, we present the development and initial evaluation of a vector space model-based algorithm to calculate researcher similarity using four inputs: 1) MeSH terms of publications; 2) MeSH terms and author rank; 3) exploded MeSH terms; and 4) exploded MeSH terms and author rank. We developed and evaluated the algorithm using a data set of 17,525 authors and their 22,542 papers. On average, our algorithms correctly predicted 2.5 of the top 5/10 coauthors of individual scientists. Exploded MeSH and author rank outperformed all other algorithms in accuracy, followed closely by MeSH and author rank. Our results show that the accuracy of MeSH term-based matching can be enhanced with other metadata such as author rank
Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm.
No full textAlthough 5-fluorouracil (5-Fu) combination chemotherapy provides a satisfactory therapeutic response in patients with gestational trophoblastic neoplasms (GTNs), it has severe side effects. The current study analyzed the therapeutic effects and side effects of tegafur plus actinomycin D (Act-D) vs. 5-Fu plus Act-D for the treatment of GTNs based on controlled historical records. A total of 427 GTN cases that received tegafur and Act-D combination chemotherapy at the Second Xiangya Hospital of XiangYa Medical School between August 2003 and July 2013 were analyzed based on historical data. A total of 393 GTN cases that received 5-Fu plus Act-D between August 1993 and July 2003 at the same hospital were also analyzed, which constituted the control group. The therapeutic effects, toxicity and side effects after chemotherapy were compared between the groups. The overall response rate was 90.63% in the tegafur+Act-D group (tegafur group) and 92.37% in the 5-Fu+Act-D group (5-Fu group); these rates were not significantly different (P > 0.05). However, the incidence rates of myelosuppression (white blood cell decline), gastrointestinal reactions (nausea, vomiting, dental ulcer, and diarrhea), skin lesions and phlebitis were lower in the tegafur group than in the 5-Fu group (P < 0.05). The results of this study may provide useful data for the clinical application of tegafur in GTN treatment
- …
